Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age | Zendy

Felipe A. Martínez | Zendy; Matteo Serenelli | Zendy; José Carlos Nicolau | Zendy; Mark C. Petrie | Zendy; ChernEn Chiang | Zendy; С. Н. Терещенко | Zendy; Scott D. Solomon | Zendy; Silvio E. Inzucchi | Zendy; Lars Køber | Zendy; Mikhail Kosiborod | Zendy; Piotr Ponikowski | Zendy; Marc S. Sabatine | Zendy; David L. DeMets | Zendy; Monika Dutkiewicz-piasecka | Zendy; Olof Bengtsson | Zendy; Mikaela Sjöstrand | Zendy; Anna Maria Langkilde | Zendy; Pardeep S. Jhund | Zendy; John J.V. McMurray | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age

Author(s) -

Felipe A. Martínez,

Matteo Serenelli,

José Carlos Nicolau,

Mark C. Petrie,

ChernEn Chiang,

С. Н. Терещенко,

Scott D. Solomon,

Silvio E. Inzucchi,

Lars Køber,

Mikhail Kosiborod,

Piotr Ponikowski,

Marc S. Sabatine,

David L. DeMets,

Monika Dutkiewicz-piasecka,

Olof Bengtsson,

Mikaela Sjöstrand,

Anna Maria Langkilde,

Pardeep S. Jhund,

John J.V. McMurray

Publication year - 2019

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.119.044133

Subject(s) - medicine , ejection fraction , dapagliflozin , heart failure , cardiology , endocrinology , diabetes mellitus , type 2 diabetes

The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies reduced the risk of mortality and heart failure hospitalization and improved symptoms in patients with heart failure and reduced ejection fraction. We examined the effects of dapagliflozin according to age, given potential concerns about the efficacy and safety of therapies in the elderly.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research